Combining CRISPR‐Cas9 with another gene‐editing approach, Velasquez et al. reported a CAR‐NK‐based therapy bispecific T‐cell engager (CD19‐ENG) capable of targeting CD22+ B cells leukaemia as well as also redirecting T cells to kill malignant CD19+ B cells, hence preventing any immune escape by the tumor and improving its antitumor activity. Here, CD19 is linked to neoplasm.